In China, EGFR testing rate was only 9.6% in 2010 from a national survey [34], 18.3% in 2011 from nine sites including 12,086 NSCLC patients [35], and 42.5% in 2014 from a non-interventional real world study on EGFR testing in patients with IIIB/IV NSCLC in northern China [36]. Here, EGFR is linked to non-small cell lung carcinoma.